S&P 500

5.970,84

-1,11%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
Europa
EU
Vivoryon Therapeut (VVY)
Vivoryon Therapeut (VVY) Notícias

VVY

Vivoryon Therapeut (VVY)

Vivoryon Therapeut

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:EU:VVY

1 2 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
09/07/2024	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease	EU:VVY	Vivoryon Therapeut
21/06/2024	10:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting	EU:VVY	Vivoryon Therapeut
23/05/2024	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease	EU:VVY	Vivoryon Therapeut
15/05/2024	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024	EU:VVY	Vivoryon Therapeut
08/05/2024	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024	EU:VVY	Vivoryon Therapeut
24/04/2024	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates	EU:VVY	Vivoryon Therapeut
16/04/2024	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024	EU:VVY	Vivoryon Therapeut
15/03/2024	03:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Announces Changes to Board Composition	EU:VVY	Vivoryon Therapeut
04/03/2024	03:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease	EU:VVY	Vivoryon Therapeut
08/01/2024	03:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024	EU:VVY	Vivoryon Therapeut
06/12/2023	03:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress	EU:VVY	Vivoryon Therapeut
28/11/2023	03:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023	EU:VVY	Vivoryon Therapeut
07/11/2023	03:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference	EU:VVY	Vivoryon Therapeut
26/10/2023	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision	EU:VVY	Vivoryon Therapeut
23/10/2023	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose	EU:VVY	Vivoryon Therapeut
17/10/2023	10:32	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders	EU:VVY	Vivoryon Therapeut
05/10/2023	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation	EU:VVY	Vivoryon Therapeut
15/09/2023	08:57	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board	EU:VVY	Vivoryon Therapeut
07/09/2023	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress	EU:VVY	Vivoryon Therapeut
31/08/2023	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023	EU:VVY	Vivoryon Therapeut
04/08/2023	18:35	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023	EU:VVY	Vivoryon Therapeut
04/08/2023	18:30	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer	EU:VVY	Vivoryon Therapeut
16/07/2023	04:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease	EU:VVY	Vivoryon Therapeut
21/06/2023	13:02	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting	EU:VVY	Vivoryon Therapeut
15/06/2023	12:49	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Announces CEO Transition Plan	EU:VVY	Vivoryon Therapeut
01/06/2023	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences	EU:VVY	Vivoryon Therapeut
26/05/2023	02:39	GlobeNewswire Inc.	Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million	EU:VVY	Vivoryon Therapeut
25/05/2023	12:50	GlobeNewswire Inc.	Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering	EU:VVY	Vivoryon Therapeut
16/05/2023	02:00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress	EU:VVY	Vivoryon Therapeut
09/05/2023	02:02	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023	EU:VVY	Vivoryon Therapeut